Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-370-4081
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/19/2019 (Estimated)
OptionableNot Optionable
Genprex (NASDAQ:GNPX) Frequently Asked Questions
What is Genprex's stock symbol?
Genprex trades on the NASDAQ under the ticker symbol "GNPX."
How were Genprex's earnings last quarter?
Genprex Inc (NASDAQ:GNPX) issued its earnings results on Tuesday, August, 13th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. View Genprex's Earnings History.
When is Genprex's next earnings date?
What price target have analysts set for GNPX?
2 brokers have issued twelve-month target prices for Genprex's shares. Their predictions range from $3.00 to $5.00. On average, they anticipate Genprex's stock price to reach $4.00 in the next year. This suggests a possible upside of 701.9% from the stock's current price. View Analyst Price Targets for Genprex.
What is the consensus analysts' recommendation for Genprex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genprex.
What are Wall Street analysts saying about Genprex stock?
Here are some recent quotes from research analysts about Genprex stock:
- 1. According to Zacks Investment Research, "Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small cell lung cancer. Genprex Inc. is based in United States. " (6/18/2019)
- 2. Maxim Group analysts commented, "Genprex reported 3Q18 with a net loss of ($2.2M) and ended the period with $10.3M in cash and cash equivalents." (11/20/2018)
Has Genprex been receiving favorable news coverage?
Press coverage about GNPX stock has been trending negative on Sunday, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genprex earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Genprex.
Are investors shorting Genprex?
Genprex saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 46,400 shares, an increase of 13.4% from the August 30th total of 40,900 shares. Based on an average trading volume of 49,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.5% of the shares of the company are sold short. View Genprex's Current Options Chain.
Who are some of Genprex's key competitors?
Some companies that are related to Genprex include Addex Therapeutics (ADDXF), Zosano Pharma (ZSAN), Acer Therapeutics (ACER), Akari Therapeutics (AKTX), Alimera Sciences (ALIM), Fibrocell Science (FCSC), Leap Therapeutics (LPTX), Clearside Biomedical (CLSD), Bio-Path (BPTH), Zafgen (ZFGN), China SXT Pharmaceuticals (SXTC), Aptevo Therapeutics (APVO), Aerpio Pharmaceuticals (ARPO), Provectus Biopharmaceuticals (PVCT) and Sierra Oncology (SRRA).
What other stocks do shareholders of Genprex own?
Who are Genprex's key executives?
Genprex's management team includes the folowing people:
- Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
- Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
- Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
- Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board
How do I buy shares of Genprex?
Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genprex's stock price today?
One share of GNPX stock can currently be purchased for approximately $0.50.
How big of a company is Genprex?
Genprex has a market capitalization of $7.90 million. The company earns $-12,370,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. View Additional Information About Genprex.
What is Genprex's official website?
How can I contact Genprex?
Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected]
MarketBeat Community Rating for Genprex (NASDAQ GNPX)
MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote "Outperform" if you believe GNPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
